Head-to-head · Cost-Efficiency Index
CoreAge Rx vs Claya
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxClaya
Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Visit ClayaThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 69. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. Claya still earns a C — Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | Claya |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 69/100 |
| Semaglutide / mo | $99/mo | $149/mo (all doses, compounded) |
| Tirzepatide / mo | $149/mo | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,188 | $1,788 |
| Tirzepatide / yr (modeled) | $1,788 | $2,388 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #97 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
Claya
69/100Where the value is
- Semaglutide is explicitly 'same price regardless of dosage' at $149/mo, removing dose-tier guesswork
- LegitScript Certified, BBB Accredited, and HIPAA Compliant badges all displayed together
- '$100 off your first month' promo code (100CLAYA) published openly with no intake required to see it
The tradeoffs
- The advertised $149/$199 rates are qualified elsewhere on the same page as available 'with select multi-month plans' — a shopper reading only the 'a month' headline could reasonably assume pure month-to-month billing when a prepay term may be required
- No state coverage list is published anywhere on the public site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.